asimadoline

09/01/2008 - "In a clinical trial in patients with IBS, average pain 2 h post-on-demand treatment with asimadoline was not significantly reduced. "
07/15/2004 - "Area under curve of pain intensity rated at each distension step was significantly lower on asimadoline (89.3 +/- 33.9, ANOVA) than on placebo (108.1 +/- 29.7) (P = 0.0411). "
04/01/2003 - "Asimadoline at 1.5 mg increased gas scores at 16 mmHg of distension (P = 0.03) and pain scores at distensions of 8 and 16 mmHg (P = 0.003 and 0.03, respectively) but not at higher levels of distension. "
01/01/2012 - "Asimadoline, to date, has shown a good safety profile and the target Phase III population - diarrhea-predominant IBS patients with at least moderate pain - was iteratively determined in a prospective manner from a Phase II dose-ranging study. "
07/15/2004 - "These data suggest that further studies should explore the potential benefit of asimadoline in treatment of pain in irritable bowel syndrome patients."

10/01/2010 - "Asimadoline in the treatment of irritable bowel syndrome."
07/01/2008 - "Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome."
07/15/2004 - "These data suggest that further studies should explore the potential benefit of asimadoline in treatment of pain in irritable bowel syndrome patients."
05/01/2016 - "Asimadoline shows efficacy in patients with moderate-to-severe irritable bowel syndrome-related pain. "
01/01/2012 - "Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review."

11/01/2007 - "Post hoc analyses suggest asimadoline was effective in mixed IBS (P = .003, unadjusted), but may be worse in diarrhea-predominant IBS (P = .065 unadjusted). "
01/01/2012 - "Asimadoline, to date, has shown a good safety profile and the target Phase III population - diarrhea-predominant IBS patients with at least moderate pain - was iteratively determined in a prospective manner from a Phase II dose-ranging study. "
01/01/2012 - "Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review."

12/01/1999 - "In naïve rats, intraplantar (i.pl.) injection of asimadoline into the nerve-injured paw, at doses of 10, 15 and 20 (but not 30) microg, dose-dependently relieved the mechanical allodynia-like behaviour. "
12/01/1999 - ", twice daily for 4 days) and naïve, saline-pretreated rats, asimadoline (15 microg, i.pl.) relieved the mechanical allodynia-like behaviour to the same extent, indicating no cross-tolerance between morphine and the peripherally-selective drug. "
11/14/2007 - "Our results indicate that systemic, intrathecal and periaqueductal grey administration of asimadoline and ICI-204448 reduces tactile allodynia. "
11/14/2007 - "Subcutaneous (s.c.) administration of asimadoline and ICI-204448 (1-30 mg/kg) dose-dependently reduced tactile allodynia. "
11/14/2007 - "Subcutaneous, intrathecal and periaqueductal grey administration of asimadoline and ICI-204448 reduces tactile allodynia in the rat."

01/01/2022 - "This prospective, 4-week, placebo-controlled, cross-over study aimed to investigate the efficacy of 1% topical κ-opioid agonist, asimadoline, in a model of canine atopic dermatitis (AD). "
01/01/2022 - "Topical κ-opioid receptor agonist asimadoline improves dermatitis in a canine model of atopic dermatitis."